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Abstract Craniopharyngiomas are locally aggressive
tumors which typically are focused in the sellar and
suprasellar region near a number of critical neural and
vascular structures mediating endocrinologic, behavioral,
and visual functions. The present study aims to summarize
and compare the published literature regarding morbidity
resulting from treatment of craniopharyngioma. We per-
formed a comprehensive search of the published English
language literature to identify studies publishing outcome
data of patients undergoing surgery for craniopharyngioma.
Comparisons of the rates of endocrine, vascular, neuro-
logical, and visual complications were performed using
Pearson’s chi-squared test, and covariates of interest were
ﬁtted into a multivariate logistic regression model. In our
data set, 540 patients underwent surgical resection of their
tumor. 138 patients received biopsy alone followed by
some form of radiotherapy. Mean overall follow-up for all
patients in these studies was 54 ± 1.8 months. The overall
rate of new endocrinopathy for all patients undergoing
surgical resection of their mass was 37% (95% CI = 33–
41). Patients receiving GTR had over 2.5 times the rate of
developing at least one endocrinopathy compared to
patients receiving STR alone or STR ? XRT (52 vs. 19 vs.
20%, v
2 P\0.00001). On multivariate analysis, GTR
conferred a signiﬁcant increase in the risk of endocrinop-
athy compared to STR ? XRT (OR = 3.45, 95% CI =
2.05–5.81, P\0.00001), after controlling for study size
and the presence of signiﬁcant hypothalamic involvement.
There was a statistical trend towards worse visual out-
comes in patients receiving XRT after STR compared to
GTR or STR alone (GTR = 3.5% vs. STR 2.1% vs.
STR ? XRT 6.4%, P = 0.11). Given the difﬁculty in
obtaining class 1 data regarding the treatment of this tumor,
this study can serve as an estimate of expected outcomes
for these patients, and guide decision making until these
data are available.
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Introduction
Craniopharyngiomas are locally aggressive tumors which
typically are focused in the sellar and suprasellar region
near a number of critical neural and vascular structures
mediating endocrinologic, behavioral, and visual functions.
Multimodality therapy for these tumors can be challenging,
given the signiﬁcant potential for harm with any inter-
vention involving the structures in this region, as well as
the young age of many of the patients with these lesions.
For many years, gross total resection (GTR) was felt to
be the treatment of choice, given the better rates of tumor
control compared to subtotal resection (STR) alone, and the
avoidance of radiotherapy in young patients. Experience
with aggressive surgical resection has led some to conclude
that a general goal of GTR in all cases might lead to
unacceptable rates of endocrinologic and behavioral mor-
bidity, and that GTR could be replaced with subtotal
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[1–4]. This potential beneﬁt must be tempered against the
risk of radiation induced injury to nearby radiosensitive
normal structures, notably the optic chiasm [5, 6]. The
present study aims to summarize and compare the pub-
lished literature regarding morbidity resulting from treat-
ment of craniopharyngioma.
Materials and methods
Article selection
Articles were identiﬁed via a PubMed search using the key
phrases ‘‘craniopharyngioma,’’ alone and in combination
with ‘‘optic,’’ ‘‘morbidity,’’ ‘‘pituitary,’’ ‘‘hypopituita-
rism,’’ ‘‘endocrine,’’ ‘‘complications,’’ ‘‘visual,’’ and
‘‘vision.’’ Inclusion criteria were: (1) All patients had to
have follow-up data available. (2) Articles had to have
enough information for each patient to be disaggregated.
The rationale for the exclusion of aggregated data sets is
described below. Exclusion criteria were: (1) Articles that
combined patient outcomes of craniopharyngioma with
other childhood tumors were excluded, unless there was a
clear distinction between the two separate groups of
patients. (2) Rathke’s Pouch tumors were excluded from
this study. After reviewing these articles, a thorough
review of all referenced sources was also performed.
All references that contained disaggregated data
speciﬁcally addressing complication rates with adequate
follow up in patients who had undergone surgical resection
with or without fXRT or stereotactic radiosurgery (SRS) as
adjuvant or monotherapy were included in our analysis. In
addition, we included patients undergoing surgery via the
extended transsphenoidal route in the surgery cohort,
where appropriate.
Data extraction
Our searches yielded a total of 274 studies [3, 7–279]
(Table 1) reporting data for 8058 non-duplicated cranio-
phayngioma patients. After analyzing the complication
rates in aggregated cohorts, we concluded that complica-
tion rates were likely underreported in aggregated data sets
(for example, the reported rate of endocrinopathy with
GTR was 2.1% in the aggregated datasets, compared with a
more realistic 52% in series which presented individual
patients separately). Thus, we chose to analyze only these
disaggregated datasets.
Disaggregated data useable for analysis were presented
for 800 individual patients. Data were stratiﬁed into ﬁve
groups based on treatment paradigm: STR alone, GTR
alone, STR plus adjuvant post-operative radiotherapy
Table 1 Pubmed ID’s of identiﬁed studies
102623 3984798 8607079 11322455 15141142 16700314
290201 4084876 8748817 11345343 15185112 16700318
290203 4308176 8869189 11441284 15206435 16798405
290204 4542715 8869774 11465396 15272926 16825115
290207 5059968 8883637 11515727 15290187 16850111
408309 5573248 9007857 11585327 15322844 16888556
430156 5648949 9068702 11685525 15335421 17015135
615967 5821004 9112447 11740179 15367800 17041520
622676 5842310 9224913 11769865 15558704 17042979
928713 6156805 9298276 11810394 15570985 17046151
975700 6168950 9361074 11841735 15670196 17161483
1011020 6293388 9361075 11862438 15681858 17185886
1110394 6381061 9364961 11938361 15759158 17233305
1174243 6470759 9440495 11942362 15800425 17330531
1403127 6511526 9482551 11949829 15807869 17337922
1414528 6657077 9728244 11961313 15851090 17407137
1527612 6673882 9782245 11981627 15871507 17415187
1669245 6833018 9806520 11990811 15895298 17469176
1727168 6853252 9814465 12060820 15928963 17533510
1772600 6886754 9840379 12062594 15931512 17566208
1803868 7099406 9950494 12099569 15957193 17592268
1955511 7104980 9950495 12116534 15959732 17627142
2002381 7105886 10066013 12134929 15959733 17762741
2013769 7121821 10070421 12197795 15959734 18311527
2080379 7264728 10086237 12243827 15959735
2095298 7413035 10232528 12376777 15965667
2116387 7431164 10424206 12382167 15971075
2204689 7438834 10433322 12419438 15989759
2311109 7530989 10445444 12420123 15995885
2352012 7530989 10461071 12447234 16001286
2398383 7568823 10616560 12456941 16028088
2441286 7596502 10616561 12495299 16034620
2494851 7616262 10659012 12507105 16044343
2501242 7619722 10681689 12507107 16055476
2672706 7673031 10690718 12555247 16124175
2689398 7818929 10703499 12677102 16133275
2894566 7841079 10726829 12786772 16133276
2912938 7841080 10760417 12820755 16133277
3336845 7841081 10867561 12823875 16175850
3396018 7841082 10883334 12825216 16216361
3396019 7841084 10892270 12845200 16320025
3442400 7841085 10975938 12922045 16327556
3489356 7885544 11013625 12925239 16383245
3628817 7942198 11014425 14519213 16500745
3712025 8021691 11118572 14558670 16580494
3738985 8027806 11124639 14961770 16630407
3794057 8272006 11131489 14967425 16700308
3799245 8327728 11143262 15035280 16700310
3968554 8422329 11155065 15040718 16700311
3968556 8438080 11234912 15046646 16700313
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123(STR ? XRT), biopsy followed by fractionated radiother-
apy (fXRT), or biopsy followed by radiosurgery (SRS)
alone. We did not directly compare the radiation only
groups (SRS and fXRT) to the surgically treated patients.
Endocrinopathy was deﬁned as the development of any
new monohormonal or polyhormonal anterior hypopitu-
itarism, or diabetes insipidus. Vascular injury referred to
any gross injury to the circle of Willis or perforating vessel,
as well as any reported post-treatment cerebral infarction.
Neurologic injury referred to the development of a post-
treatment non-endocrine, non-visual neurologic deﬁcit.
Visual deterioration was deﬁned as permanent loss or
decrease in visual acuity, or a new visual ﬁeld cut in either
eye. Studies which did not present patient data in a way
that these variables could reliably be determined were
excluded from further analysis.
Statistical analysis
Pearson’s v
2 test was used to analyze for differences in
categorical factors. Fisher’s exact test was used if there
were less than ﬁve values per cell. Analysis of variance
(ANOVA) was used to evaluate for statistical differences in
pre-operative continuous factors, including age and tumor
size. Post-hoc between group analyses were performed
when the ANOVA demonstrated P\0.05 using Tukey’s
test. All analyses were carried out using SPSS version 16.0
(SPPS, Inc.).
Logistic regression analysis
Univariate analysis was used to identify covariates which
might affect the rate of neurologic, endrocrinologic, vas-
cular, or visual complications in these patients. Binary and
categorical variables were compared using Pearson’s v
2
test, or the v
2 test for trend, respectively. Cut-offs for
variables were determined empirically by ﬁrst analyzing
the data in smaller categories, and then aggregating groups
which seemed statistically homogeneous. Variables which
impacted rates of complication with a P = 0.2 or less on
univariate analysis were included in stepwise binary
logistic regression modeling [280]. All odds ratios on
multivariate analysis, reﬂect the risk of having nonservi-
cable hearing a neurologic or endocrine complication
compared to the reference group. Reference groups inclu-
ded the STR ? XRT cohort for the extent of resection
analysis and the large sample size studies for the surgeon
experience analysis. The goodness of ﬁt of the regression
model was conﬁrmed by demonstrating a non-signiﬁcant
P-value on the Hosmer-Lemeshow test [280, 281].
We tested interaction terms between each of the three
variables to signiﬁcantly impact hearing on univariate
analysis. The statistical signiﬁcance of the interactions was
assessed with the use of backward stepwise regression, in
which statistical signiﬁcance was estimated by means of the
likelihood-ratio test to assess the effect of removing inter-
action terms for all strata of the given variable [280]. After
ﬁndingthatnoneoftheinteractiontermswouldsigniﬁcantly
(unadjusted P[0.2 for all terms) alter the log likelihood of
the regression model if removed, we calculated the adjusted
odds ratios without adjusting for interactions.
Of note, while tumor size is a variable of interest, it is
inconsistently presented in most studies, and we were only
able to collect data on tumor size for 87 patients. Because
these data were not enough to include in the multivariate
regression modeling, we present only univariate data
regarding the relationship between tumor size and
complications.
Results
Clinical characteristics of included patients
In our data set, 540 patients underwent surgical resection of
their tumor. GTR was achieved in 289 cases, while STR
was achieved in 251 cases. Of patients receiving STR, 110
patients received fXRT, and 141 did not. Surgical patients
in different cohorts did not differ in mean age at the time of
surgery, gender distribution, or pre-operative tumor size.
138 patients received biopsy alone followed by some
form of radiotherapy. 72/138 of these patients received
fXRT, and 66/138 patients received SRS. Age and gender
distribution did not differ between patients receiving fXRT
and SRS.
The remaining patients did not have adequate data to
facilitate our analysis and were excluded. Mean overall
follow-up for all patients in these studies was 54 ±
1.8 months.
The mean number of patients per study was 5.8 patients,
(range 1–45 patients per study). 34% of the patients in the
studycamefromseriesof10orlesspatients,22%camefrom
series of 10–20 patients, and 43% came from series larger
than 20 patients. The modest sample sizes in many of the
includedstudiesisaninevitableconsequenceofthedecision
to use only disaggregated data, as larger studies generally
provide summary statistics instead of individual patient
data, and as discussed below, frequently do not report rates
of morbidity in a way which can be realistically analyzed.
The rates of neurologic injury after treatment
for craniopharyngioma
New neurologic deﬁcits were reported in 5.1% of patients
undergoing surgery (95% CI = 3.3–7.1), and in 2.2% of
patients undergoing fXRT or SRS alone (95% CI = 0–4.6)
J Neurooncol (2011) 101:463–476 465
123(Table 2). There was no statistically signiﬁcant difference
in the rates of neurologic deﬁcits between patients receiv-
ing GTR alone, STR alone, or STR ? XRT (6.9 vs. 4.2 vs.
1.8%, P = NS) in the univariate analysis, or between
patients receiving fXRT and those receiving SRS (1.4 vs.
3.0%, P = NS) (Fig. 2).
Interestingly, on multivariate analysis, GTR conferred a
signiﬁcant increase in the risk of neurologic deﬁcits com-
pared to STR ? XRT (OR = 5.05, 95% CI = 1.15–22.21,
P = 0.03) (Table 5), after controlling for study size.
Gross total resection markedly increases the rate
of endocrinopathy
The overall rate of new endocrinopathy for all patients
undergoing surgical resection of their mass was 37% (95%
CI = 33–41) (Table 2). Table 3 summarizes the rates of
individual endocrinopathies. Signiﬁcant monoendocrinop-
athies of TSH and ACTH were reported commonly, as was
diabetes insipidus (DI). Anterior panhypopituitarism was
reported in as many as 11.8% in patients undergoing GTR.
Patients receiving GTR had over 2.5 times the rate of
developing at least one endocrinopathy compared to
patients receiving STR alone or STR ? XRT (52 vs. 19 vs.
20%, v
2 P\0.00001) (Fig. 1). The rates of endocrinopa-
thy for patients receiving fXRT alone were not reported,
and thus these data were not analyzed.
On multivariate analysis, GTR conferred a signiﬁcant
increase in the risk of endocrinopathy compared to
STR ? XRT (OR = 3.45, 95% CI = 2.05–5.81,
P\0.00001) (Table 5), after controlling for study size and
the presence of signiﬁcant hypothalamic involvement.
The rates of vascular injury after surgery
for craniopharyngioma
Vascular injury was an uncommon complication of crani-
opharyngioma surgery, occurring in just two cases (95%
CI = 0–0.9) (Table 2), both resulting in ischemic cerebral
infarction. No vascular complications were reported in any
patients undergoing radiation treatment alone.
The rates of visual decline after treatment
for craniopharyngioma
Visual decline was reported in 3.7% of patients undergoing
surgery (95% CI = 2.1–5.3), and 8.6% of patients under-
going fXRT or SRS alone (95% CI = 3.9–13.4) (Table 2).
Table 2 Summary of overall rates of morbidity
95% CI
Endocrinopathy
Surgery 33–41
fXRT/SRS 8.8–28
Vascular injury
Surgery 0–0.9
fXRT/SRS 0
Neurologic deﬁcit
Surgery 3.3–7.1
fXRT/SRS 0–4.6
Vision deterioration
Surgery 2.1–5.3
fXRT/SRS 3.9–13.4
Table 3 Summary of various
types of monohormonal and
polyhormonal endocrinopathy
following treatment of
craniopharyngioma
GTR (%) STR (%) STR ? XRT (%) fXRT SRS (%)
Hyperprolactinemia 0.0 0.0 0.9 N/A 0.0
Hypogonadism 3.5 2.1 1.8 N/A 3.0
Hypothyroid 13.8 5.7 1.8 N/A 7.6
GH deﬁciency 6.2 1.4 1.8 N/A 0.0
ACTH deﬁciency 14.5 6.4 0.9 N/A 3.0
Anterior panhypopituitarism 11.8 3.5 10.0 N/A 3.0
DI 18.7 6.4 5.5 N/A 0.0
Obesity 2.1 0.7 2.7 N/A 1.5
Any endocrinopathy 51.9 19.9 20.0 N/A 18.2
Fig. 1 Comparison of 95% conﬁdence intervals of rates of endocri-
nopathy for patients treated with different modalities for
craniopharyngioma
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123There was a statistical trend towards worse visual out-
comes in patients receiving XRT after STR compared to
GTR or STR alone (GTR = 3.5% vs. STR 2.1% vs.
STR ? XRT 6.4%, P = 0.11). Visual outcomes did not
differ between patients receiving fXRT and those receiving
SRS (11.1 vs. 6.1%, P = NS) (Fig. 2).
Univariate risk factors for morbidity
after craniopharyngioma surgery
Table 4 demonstrates univariate comparisons of rates of
morbidities with patients stratiﬁed by age, tumor size, and
extent of hypothalamic involvement. Note that in our uni-
variate analysis, Patient age was not a signiﬁcant univariate
predictor of any form of complication, regardless of where
the cut-off was placed in this analysis (one such analysis is
provided in Table 4). Extensive hypothalamic involvement
did increase the risk of endocrinologic complications,
however this was not an independent predictor of morbidity
when extent of resection was controlled for (Table 5).
As stated in the methods, while tumor size is a variable of
interest, it is inconsistently presented in most studies, and
we were only able to collect data on tumor size for 87
patients. Because these data were not enough to include in
the multivariate regression modeling, we present only uni-
variate data regarding the relationship between tumor size
and complications. Patients undergoing surgery for tumors
with a size greater than or equal to 3 cm experienced a
statistical trend towards a higher rate of neurologic com-
plications compared to patients with smaller tumors (10 vs.
0%, P = 0.06) (Table 4). The rates of endocrinologic,
vascular, and visual complications were similar between
patients with larger and smaller tumors (Fig. 3).
Fig. 2 Comparison of 95% conﬁdence intervals of rates of neuro-
logic injury for patients treated with different modalities for
craniopharyngioma
Table 4 Univariate analyses of the effect of potential confounding
variables on rates of neurologic, endocrinologic, vascular, and visual
morbidity in the published literature
Neurologic Endocrine Vascular Visual
# Patients in study
1–10 9% 2% 1% 6%
11–20 2% 7% 0% 2%
21? 1% 1% 0% 4%
P\0.001 P\0.01 P = 0.12 P = 0.45
Patient age
0–2 9% 48% 0% 4%
2.1–5 5% 41% 0% 0%
5.1–10 5% 44% 1% 2%
11–20 5% 34% 0% 2%
21–50 5% 37% 1% 4%
51? 2% 31% 0% 3%
P = 0.84 P = 0.41 P = 0.85 P = 0.73
Tumor size
\3 cm 0% 36% 0% 6%
C3 cm 10% 43% 2% 0%
P = 0.06 P = 0.33 P = 0.59 P = 0.16
Hypothalamic involvement
Minor or none 5% 40% 5% 3%
Extensive 5% 33% 5% 5%
P = 0.50 P = 0.09 P = 0.43 P = 0.35
Table 5 Multivariate logistic regression demonstrating the risk of
neurologic and endocrinologic morbidity controlling for extent of
resection, study size, and presence of extensive hypothalamic
involvement
OR 95% CI P-value
-?
Neurologic
GTR 5.05 1.15 22.21 0.03
STR 2.41 0.45 12.79 0.30
Study size 1–10 2.54 1.02 6.29 0.04
Study size 11–20 0.31 0.06 1.53 0.15
Endocrine
Extensive hypothalamic
involvement
1.28 0.78 2.08 0.33
GTR 3.45 2.05 5.81 \0.00001
STR 1.89 1.05 3.38 0.03
Study size 1–10 1.02 0.66 1.58 0.92
Study size 11–20 0.61 0.35 1.05 0.08
Note that the odds ratio for the GTR and STR groups are expressed
relative to the STR ? XRT group, and that the odds ratios for the
study size groups are expressed relative to studies with the group with
the largest study size
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123The effect of surgical experience on rates of morbidity
following treatment for craniopharyngioma
Surgical experience is generally not speciﬁcally reported in
craniopharyngioma series in the literature. Using the
sample size in these studies as a surrogate for surgical
experience, we found a signiﬁcant reduction in rates of
most complications with increasing sample size (Table 4).
More speciﬁcally, there was a linear decrease in the rates of
neurologic complications with increasing study sample size
(1–10 patients: 9%, 11–20 patients: 2%, 21? patients: 1%,
P\0.0001), and a decrease in rates of endocrinopathy
favoring studies larger than 20 patients (1–10 patients: 2%,
11–20 patients: 7%, 21? patients: 1%, P\0.01). Vascular
injuries were also only reported in small series 1–10
patients: 1%, 11–20 patients: 0%, 21? patients: 0%,
P = 0.12), however this did not reach statistical signiﬁ-
cance due to the small number of events. Rates of visual
complications did not differ between groups of different
sample size (1–10 patients: 6%, 11–20 patients: 2%, 21?
patients: 4%, P = 0.45).
On multivariate analysis, studies with small sample
sizes remained an independent predictor of increased rates
of neurologic morbidity compared to those with large
sample size (OR = 2.54, 95% CI = 1.02–6.29, P = 0.04)
(Table 5), after controlling for treatment paradigm
administered. Study sample size was not an independent
predictor of endocrinologic morbidity on multivariate
analysis.
Discussion
Currently, there are few deﬁnitive studies regarding man-
agement strategies for patients with craniopharyngiomas.
This study aims to utilize a systematic collection of the
published data on craniopharyngioma, to critically evaluate
the idea that subtotal resection with adjuvant radiotherapy
can serve as a desirable replacement for gross total resec-
tion, with lower post-surgical rates of monohormonal and
panhormonal hypothalamic/pituitary endocrinopathy.
Based on our analyses, endocrinopathy is a common
iatrogenic complication of treatment of craniopharyngio-
mas with either surgical resection or radiosurgery, however
it is not unexpectedly higher with surgery. Gross total
resection markedly increases the rate of hormonal distur-
bances compared to subtotal resection with or without
radiotherapy, with over half of patients experiencing at
least one endocrinopathy, and over 10% of patients being
left with panhypopituitarism. Even after correcting for as
many covariates as the data would allow, GTR still
increased the rate of post-operative endocrinopathy by over
three fold. These data support the concept that attempting
gross total resection in these lesions is a difﬁcult trade of
endocrine function for tumor control, and that subtotal
resection might be better for the patient’s overall quality of
life. Further, previous work focusing on craniopharyngi-
oma suggests that craniopharyngiomas frequently recur
despite GTR, and that subtotal resection followed by
adjuvant radiotherapy provides similar rates of tumor
control to that achieved with gross total resection [282].
Taken together, these data argue that gross total resection
of craniopharyngiomas may not be the best treatment
option for most patients, however further work speciﬁcally
focusing on the quality of life concerns of patients under-
going these treatment paradigms is needed to deﬁnitively
conclude that STR ? XRT is better for the patients than
GTR.
The remaining argument against adjuvant radiation in
this region is the risk of visual deterioration with admin-
istering radiotherapy or radiosurgery in close proximity to
the optic apparatus. In our study, all irradiated patient
cohorts experienced an increased rate of visual compro-
mise compared to surgery only cohorts. While adjuvant
radiotherapy following subtotal cytoreductive surgery did
not reach statistical signiﬁcance for worse visual outcomes,
It is possible that a lack of statistical power in our cohort
prevented statistical signiﬁcance that would have been
demonstrated by a larger study. It is important to note that
this difference might be as large as a 10% in visual decline
over GTR at the extremes of the conﬁdence intervals,
which would be a serious argument in favor of eliminating
the need for XRT with GTR. This idea clearly deserves
additional inquiry, especially for driving subtotal resections
towards a targeted attack aimed at creating distance
between the tumor and the optic apparatus.
Additionally, our analysis demonstrates that experience
with craniopharyngiomas matters, and that experienced
surgeons have lower rates of complications, even after
Fig. 3 Comparison of 95% conﬁdence intervals of rates of visual
compromise for patients treated with different modalities for
craniopharyngioma
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123correcting for tumor characteristics, and surgical philoso-
phy. More speciﬁcally, using study size as a surrogate for
surgical experience, more experienced surgeons have lower
rates of neurologic complications than less experienced
surgeons. We speculate that increased familiarity with the
pathoanatomy of these tumors, combined with decreased
need for brain retraction by experienced surgeons, leads to
decreased rates of injury of surrounding neural structures.
Study limitations
While these ﬁndings represent a helpful summary of the
published literature on this topic, an analysis of published
data is limited by the data published by others, and may
reﬂect source study biases. It is impossible for us to control
for the quality of the data reported in the literature. For
example, the majority of this data set is derived from self-
reported outcomes largely assessed by the treating surgeon
and colleagues. It is impossible for us to assess or control
for the quality of the data reported in the literature, or the
unwillingness to report complications. Such omissions
would inevitably change the rates reported in our study.
Further, subjectively deﬁned variables, such as histologic
diagnosis, extent of resection, and the adequacy of radia-
tion therapy likely vary between studies, and we cannot
independently conﬁrm the validity of these deﬁnitions in
other groups’ publications.
Finally, due to the diverse range of data presentation, the
number of variables able to be studied and controlled for is
limited. Variables that might be of interest which are
inconsistently presented across studies cannot be reviewed.
Speciﬁcally, we cannot completely control for the effect of
tumor size on rates of complications, because unfortu-
nately, not everyone publishes these data.
Conclusion
In this study, we summarized and compared the rates of
endocrine, neurologic, vascular, and visual complications
reported in craniopharyngioma patients. Given the difﬁ-
culty in obtaining class 1 data regarding the treatment of
this tumor, this study can serve as an estimate of expected
outcomes for these patients, and guide decision making
until these data become available.
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